Lung

The treatment approaches for lung cancer are rapidly evolving, and include integration of new systemic therapies (e.g. immunotherapy and targeted therapies) into combined modality approaches for non-metastatic disease and ablative radiation therapy approaches for oligo-metastatic disease. This session will review recent literature and guidelines for the treatment of lung cancer, and provide insights into tailoring of different combined modality therapy options for patients.  

Participants will learn about the clinical outcomes and toxicity risks, and how to coordinate these new, complex multidisciplinary treatment approaches.

Furthermore, this session will review recent insights into toxicity risks for both conventional radiation therapy (especially in the postoperative setting and related to cardiac injury) and stereotactic body radiation therapy (especially for ultracentral tumors), and the implications of radiation therapy toxicity on newer combined modality approaches.

Target Audience

The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this  activity, participants should be able to do the following:

  • Discuss the literature supporting novel combined modality therapy approaches that include immunotherapy, chemotherapy, surgery and/or radiation therapy in non-metastatic lung cancer.
  • Discuss the pros and cons of different modalities of local therapy (surgery versus radiation) for each stage of lung cancer and appropriate situations to consider dual local therapy.
  • Describe risk factors for severe radiation-related toxicity, including cardiac injury and central mediastinal structure injury for SBRT, and methods to mitigate these risks.

 

Course summary
Available credit: 
  • 1.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.75 Certificate of Attendance
    This activity was designated for 1.75 AMA PRA Category 1 Credit™.
Course opens: 
04/22/2024
Course expires: 
04/28/2026
Cost:
$0.00
Rating: 
0

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.75 Certificate of Attendance
    This activity was designated for 1.75 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.